Table 2.
Prognostic relevance of lymph node harvest in stage II colon cancers
| First author | Year | n | Insuff.-rate | pT3/4 | Prognostic | Endpoints | Cut off | Survival |
| Swanson | 2003 | 35787 | 60% | 100% | Yes | 5yOS | No cut off | linear increase of 5yOS-rate |
| Law | 2003 | 115 | NA | 100% | Yes | 5yOS, 5yDFS | ≥ 7 | 5yOS: < 7LN 69% vs > 6LN 89% |
| Bui | 2006 | 4531 | NA | NA | Yes | OS | 1-3 vs 10-36 | HR = 0.6 (CI: 0.4-1.0), P = 0.03 |
| Bilimoria | 2008 | 142009 | NA | 59% | Yes | 5yOS | ≥ 12 | HR = 0.75 (CI: 0.71-0.8), P < 0.0001 |
| Maggard | 2009 | 11263 | NA | 69% | Yes | 5yOS | 4 (T1) and 10 (T2) | T1: HR = 0.76 (CI: 0.641-0.902), P = 0.002 |
| T2: 0.853 (CI: 0.776-0.937), P = 0.001 | ||||||||
| Stocchi | 2011 | 901 | NA | 100% | Yes | OS, DFS, CsS | ≥ 12 | < 12 LN: HR = 1.93 (1.27-2.94), P = 0.002 |
| Sato | 2011 | 1476 | 56% | 100% | Yes | 5yOS | > 12 | ACT: improved 5yOS for LNs ≤ 12 |
1
Sub-group of the study collection. NA: No available data; 5yOS: 5 years overall survival; 5yDFS: 5 years disease-free survival; OS: Overall survival; CsS: Cancer specific survival; ACT: Adjuvant chemotherapy; LN: Lymph node.